Scholars Journal of Applied Medical Sciences
Abbreviated Key Title: Sch J App Med Sci
ISSN 2347-954X (Print) | ISSN 2320-6691 (Online)
Journal homepage: https://saspublishers.com

OPEN ACCESS

Otolaryngology & Head-Neck Surgery

The Association between Papillary Thyroid Carcinoma and Thyroid Stimulating Hormone (TSH)

Dr. Md. Mahafuzul Huq Mamun[1*], Dr. Dipan Kumar Sarker[2], Dr. Md. Ibne Golam Sabbir[3], Dr. Md. Fakhrul Alam[4], Dr. Md. Arifur Rahman[5]

[1]Assistant Professor, Department of Otolaryngology & Head-Neck Surgery, TMSS Medical College, Bogura, Bangladesh
[2]Associate Professor, Department of Otolaryngology & Head-Neck Surgery, TMSS Medical College, Bogura, Bangladesh
[3]Assistant professor, Department of Surgery, TMSS Medical College, Bogura, Bangladesh
[4]Assistant professor, Department of ENT, ZH Sikder Women's Medical College & Hospital (Pvt.) Ltd, Dhaka, Bangladesh
[5]Assistant professor, Department of Pathology, TMSS Medical College, Bogura, Bangladesh

DOI: 10.36347/sjams.2023.v11i03.020 | **Received:** 03.12.2022 | **Accepted:** 14.01.2023 | **Published:** 22.03.2023

***Corresponding author:** Dr. Md. Mahafuzul Haque Mamun
Assistant Professor, Department of Otolaryngology & Head-Neck Surgery, TMSS Medical College, Bogura, Bangladesh

Abstract **Original Research Article**

Background: The results of thyroid-stimulating hormone (TSH) and thyroid hormones on the improvement of human Papillary thyroid cancer (PTC) stay poorly understood. TSH is an increase component that stimulates thyroid tissue to produce thyroid hormone; additionally, it influences the increase of thyroid cells and thyroid cancers cells. ***Objectives:*** The aim of this study is to assess the Association between Papillary Thyroid Carcinoma and Thyroid Stimulating Hormone (TSH). ***Methods:*** This is an observational study. The study used to be carried out in the admitted patient's Department of Otolaryngology & Head-Neck Surgery, TMSS Medical College, Bogura, Bangladesh and Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh. The duration of the period from March 2019 to February 2020. Data was entered in MS Excel and Statistical analysis was done using SPSS trial version. ***Results:*** This study indicates that in accordance to age distribution of 70 Patients. Here in accordance to Age distribution, 3(4.28%) have been <30, 11(15.72%) have been 30-39, 14(20%) have been 40-49, 15(21.43%) had been 50-59, 21(30%) had been 60-69 and 6(8.57%) had been ≥70. And in accordance to gender (14.28%) had been Male, (85.72%) have been Female. ***Conclusion:*** We found a significantly extended threat of PTC related with TSH levels under the ordinary range amongst women and with TSH tiers above the normal range amongst men.

Keywords: Thyroid-stimulating hormone (TSH), Papillary thyroid cancer (PTC), Thyroid hormone.

INTRODUCTION

Thyroid cancer is by far the most common type of endocrine malignancy and accounts for most deaths caused by all of the endocrine tumors combined [1]. In the United States, thyroid cancer are the ninth most frequent cancer, accounting for 3.8% of all malignancies and 0.3% of all deaths from cancer [2]. The most frequent histologic kind of thyroid cancer are Papillary thyroid cancer (PTC), which 80% of all thyroid carcinomas [3]. The causal elements underlying thyroid cancers are poorly understood. The most well-established chance elements for thyroid cancers include increased age, female gender, publicity to ionizing radiation, records of benign thyroid disorder [4]. Recent research has recognized greater body weight and height as danger elements for thyroid cancer [5].

Thyroid-stimulating hormone (TSH) is the cells and regulator of thyroid functions. It controls the procedures that lead to extended thyroid hormone manufacturing and secretion [6]. Blood concentrations of thyroid hormones inversely alter the launch of TSH at the pituitary levels. High TSH stage has been related with PTC pathogenesis in a mouse model [7]. Suppression of TSH is presently encouraged to control patients with differentiated thyroid cancer (DTC), which has proven advantages to patient survival [8]. Thyroid hormones have additionally been suggested to have a tumor-promoting impact on various cancers, including pancreatic, breast, ovarian, and prostate cancers [9]. However, epidemiologic research findings link TSH and thyroid hormones to the threat for human life [10].

The majority of early research stated an extended chance of thyroid cancers related with TSH levels [11], various researches found no enormous association [12], and one stated a decreased risk [13]. All research that stated a high-quality affiliation between TSH and thyroid cancer had been cross-sectional or case–control studies [14]. Therefore, the opportunity of reverse causation or treatment impact ought to be of potential concern due to the fact the TSH stages had been measured after diagnosis. There are only three preceding potential cohort studies. One stated a drastically decreased hazard of thyroid cancers related with improved TSH levels [15]. Two smaller researches pronounced lower, however now not significant, TSH stages in thyroid cancers instances than in controls. The relationship between thyroid hormones and risk of thyroid cancer have additionally been inconclusive. Two researches determined that decrease thyroid hormone had been related with a greater chance of thyroid cancer, while the remaining five reported no suggestion [16].

In light of the inconclusive associations between TSH, thyroid hormones, and thyroid cancer, we carried out a nested case–control find out about the use of data from the Department of Defense (DoD) Automated Central Tumor Registry (ACTUR) and the Defense Medical Surveillance System (DMSS), with prediagnostic serum samples from the Department of Defense Serum Repository (DoDSR) to look at the associations of PTC with TSH and thyroid hormones.

METHODS

This is an observational study. The study used to be carried out in the admitted patient's Department of Otolaryngology & Head-Neck Surgery, TMSS Medical College, Bogura, Bangladesh and Shaheed Ziaur Rahman Medical College, Bogura, Bangladesh and the duration of the period from March 2019 to February 2020. This study was carried out on 70 patients the find out about the population including male and female patients. The choice of treatment was made by the patient after a full discussion with the Otolaryngology & Head-Neck surgeon and multidisciplinary team. The data for this study about had been accumulated from patients' medical information and radiographs. Statistical evaluation of the results used to be got via the use of a window-based computer software program devised with Statistical Packages for Social Sciences (SPSS-24).

RESULTS

Table 1: Distribution of the study according to age

Age Distribution	n=70	%
<30	3	4.28
30-39	11	15.72
40-49	14	20
50-59	15	21.43
60-69	21	30
≥70	6	8.57

Table 1 demonstrated the age of 51 Patients aged <30 to ≥ 70 years. Here according to Age distribution, 3(4.28%) were <30, 11(15.72%) were 30-39, 14(20%) were 40-49, 15(21.43%) were 50-59, 21(30%) were 60-69 and 6(8.57%) were ≥70.



Figure 1: Distribution of the study according to sex

The total study population was 70 patients, according to gender (14.28%) were Male, (85.72%) were Female.

Table 2: Distribution of the study according to Incidence of malignancy

Histopathology	n=70	%
Malignancy	17	24.29
Benign	53	75.71

Table 2 demonstrated the distribution of the study according to Incidence of malignancy. Here according to Histopathology, 17(24.29%) were Malignancy and 53(75.71%) were 75.71.

Table 3: TSH concentration in various thyroid malignancy

Variable	n=70	TSH mIU/I) Mean±SD	T	P
Follicular carcinoma	5	3.30±1.14	35.109	0.000
Hurthle cell carcinoma	1	3.07±0.90		
Papillary carcinoma	11	4.84±0.41		
Benign	53	3.35±0.82		

Table 3 demonstrated the TSH concentration in various thyroid malignancy. Here according to Variable, 5(3.30±1.14) were Follicular carcinoma, 1(3.07±0.90) were Hurthle cell carcinoma, 11(4.84±0.41) were Papillary carcinoma and 53(3.35±0.82) were Benign.

Table 4: TSH and malignancy correlation

TSH	Histopathology		Sensitivity	Specificity	PPV	NPV
	Malignancy	Benign				
>3.91	3	13	72.7	74.5	48.8	89.1
>4.05	5	15	72.7	80.0	54.8	89.8
>4.14	6	21	70.9	83.0	58.2	89.5
>4.33	2	3	61.8	91.5	70.8	87.8
>4.56	1	1	56.4	97.0	86.1	87.0

Table 4 demonstrated the TSH and malignancy correlation. When TSH were >3.91, Malignancy was 3, Benign were 13, Sensitivity was 72.7, Specificity was 74.5, PPV were 48.8 and NPV were 89.1. When TSH were >4.05, Malignancy was 5, Benign were 15, Sensitivity was 72.7, Specificity was 80.0, PPV were 54.8 and NPV were 89.1. When TSH were >4.14, Malignancy was 6, Benign were 21, Sensitivity was 70.9, Specificity was 83.0, PPV were 58.2 and NPV were 89.5. When TSH were >3.91, Malignancy was 3, Benign were 13, Sensitivity was 72.7, Specificity was 74.5, PPV were 48.8 and NPV were 89.1. When TSH were >4.56, Malignancy was 1, Benign were 1, Sensitivity was 56.4, Specificity was 97.0, PPV were 86.1 and NPV were 87.0.

DISCUSSION

There had been several researches discovering and discussing the position and informativeness of serum TSH attention dimension in interpretation of the hazard of PTC and its prognosis. For instance, a number of meta-analyses confirmed that greater TSH levels have been related with a multiplied thyroid cancers risk [17]. However, most of the research chosen for evaluation has been cross-sectional research and measured TSH levels after treatment of thyroid cancer started and ought to be fallacious due to outcomes of treatment [18]. Most of the research manipulates groups comprised patients with thyroid nodules or patients undergoing surgical treatment for a suspicious thyroid tumor [19]. In fact, some types of independent thyroid nodules have been related with alteration of thyroid hormones manufacturing that may want to lead to secondary adjustments of TSH production [20].

In our study, according to Age distribution, 3(4.28%) were <30, 11(15.72%) were 30-39, 14(20%) were 40-49, 15(21.43%) were 50-59, 21(30%) were 60-69 and 6(8.57%) were ≥70. And according to gender (14.28%) were Male, (85.72%) were Female.

TSH level considerably differed in patients with benign tumors and PTC. Partly these variations had been associated to greater charge of coexisting HT amongst patients with PTC. There have been no significant variations in TSH levels when in contrast between patients with FA and PTC with no HT. [21] In fact, most of the patients with PTC validated ordinary and low regular levels of PTC. And only about 6,42% of patients with PTC had TSH levels greater than the ordinary range. It is vital to underline that most of these patients had coexisting that ought to lead to serum TSH elevation.

The perception postulating the function of TSH in PTC improvement is primarily based on TSH has an impact in stimulation of follicular cells proliferation. [22] As it is broadly accepted, TSH performs a necessary position in regulating thyroid characteristic along with stimulation of proliferation of follicular cells, their measurement and secretory

activity. The principal mechanisms of TSH actions are in the main mediated through TSHR that is related with Gas-protein activating adenylyl cyclase-cyclic adenosine monophosphate (cAMP) - protein kinase A-pathway [23]. This signaling pathway performs the indispensable function in follicular cells differentiation and purposeful activities. There are some researches postulating that somatic TSHR mutations in thyroid epithelial cell can additionally prompt the cAMP pathway, which enables the cell increase and clonal expansion, main to the formation of an autonomously functioning thyroid adenoma [24]. Although activated cAMP pathway results in more desirable growth, it is now not ample for malignant transformation of ordinary thyrocytes. It was proven that TSHR-mutations are related with numerous illnesses like familial gestational hyperthyroidism, autonomous toxic adenomas, hereditary or sporadic poisonous thyroid hyperplasia, familial on-autoimmune hyperthyroidism, Graves' disease and autoimmune hypothyroidism however not often happen in thyroid cancer [25].

High TSH level used to be related with HT. Coexistence of HT and PTC predominated amongst women. Although there are some debates about the position of HT in PTC improvement there is strong proof demonstrating the function of autoimmune infection in papillary microcarcinoma and PTC [26]. Inflammation reasons oxidative cells injury and reactive oxygen species formation that may additionally motive DNA damage, ensuing in mutations that subsequently can lead to malignant transformation and PTC development [27]. Dailey *et al.,* used to be the first who proposed an affiliation between HT and PTC many years ago [28]. In fact, the incidence of PTC improvement in patients with such autoimmune thyroid lesions as HT and Grave's disease is 3–5 instances greater than in patients except inflammatory lesions of thyroid gland [29].

In our present study, according to Variable, 5(3.30±1.14) were Follicular carcinoma, 1(3.07±0.90) were Hurthle cell carcinoma, 11(4.84±0.41) were Papillary carcinoma and 53(3.35±0.82) were Benign and according to TSH and malignancy correlation. When TSH were >3.91, Malignancy was 3, Benign were 13, Sensitivity was 72.7, Specificity was 74.5, PPV were 48.8 and NPV were 89.1. When TSH were >4.05, Malignancy was 5, Benign were 15, Sensitivity was 72.7, Specificity was 80.0, PPV were 54.8 and NPV were 89.1. When TSH were >4.14, Malignancy was 6, Benign were 21, Sensitivity was 70.9, Specificity was 83.0, PPV were 58.2 and NPV were 89.5. When TSH were >3.91, Malignancy was 3, Benign were 13, Sensitivity was 72.7, Specificity was 74.5, PPV were 48.8 and NPV were 89.1. When TSH were >4.56, Malignancy was 1, Benign were 1, Sensitivity was 56.4, Specificity was 97.0, PPV were 86.1 and NPV were 87.0.

TSH ranges above the normal range have been only related with a multiplied threat of PTC amongst men. There used to be an inverse affiliation between PTC and TSH levels inside the regular range amongst each man and women. The discovered associations diverse extremely via histologic subtypes and via tumor measurement (_10 vs. >10 mm) amongst men and women [30]. The gender impact on the affiliation between TSH and PTC used to be only discovered amongst classical PTC cases. TSH stages confirmed a strong desirable affiliation with PTC with large tumor size. A suggestive inverse affiliation between greater TT3 levels and danger of PTC used to be located amongst men.

The inverse developments between TSH ranges and danger of PTC determined in the current study about have been in accordance with effects from a nested case–control study within a massive population-based potential cohort in Europe [31]. The cohort consisted of about 520,000 healthy individuals of ages 35 to 69 years when recruited between 1992 and 1998 in 10 European countries. A whole of 357 incident thyroid cancers instances (57 men and 300 women) identified at some stage in 1992 to 2009 and 767 matched controls have been included in the analyses. Blood samples had been amassed at enrollment. An inverse dose–response relationship between standard TSH levels and chance of differentiated thyroid cancer. However, as in contrast with the European study, our populace was younger and healthier [32], with individuals of a while 17 to 56 years at blood samples collection. The existing learn about found inconsistent associations between TSH ranges and danger of PTC amongst ladies as in contrast to men, whereas the European find out about suggested comparable associations amongst men and women. There had been two other potential researches with smaller pattern measurement that investigated the affiliation between TSH and hazard of thyroid cancer [33]. Although no extensively inverse affiliation was once located in these studies, each suggested decrease TSH levels amongst thyroid cancers instances than controls. The serum concentrations of TSH and thyroid hormones have been prospectively assessed and have been no longer influenced by means of the disease technique or treatment, which furnished a possibility to estimate probably causal relationships between TSH, thyroid hormones, and thyroid cancer [34].

Limitations of the Study

The present study was conducted in a very short period due to time constraints and funding limitations. The small sample size was also a limitation of the present study.

CONCLUSION

In conclusion, the current study about confirmed the experimental associations different via histologic subtype and tumor size. These consequences

should have significant medical implications for physicians who are managing patients. Future research is warranted to in addition recognize these associations.

RECOMMENDATION

This study can serve as a pilot to a much larger research involving multiple centers that can provide a nationwide picture, validate regression models proposed in this study for future use and emphasize points to ensure better management and adherence.

ACKNOWLEDGEMENTS

The wide range of disciplines involved in The Association between Papillary Thyroid Carcinoma and Thyroid Stimulating Hormone (TSH) research means that an Editor needs much assistance from referees in the evaluation of papers submitted for publication. I am very grateful to many colleagues for their thorough, helpful and usually prompt response to requests for their opinion and advice.

DECLARATION

Funding: None funding sources.

Conflict of Interest: The authors state that the publishing of this paper does not include any conflicts of interest.

Ethical Approval: The study was approved by the informed consent of the participant patients.

REFERENCES

1. Chen, A. Y., Jemal, A., & Ward, E. M. (2009). Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 115(16), 3801-7.
2. Howlader, N. N., Noone, A. M., Krapcho, M., Garshell, J., Neyman, N., Altekruse, S. F., Kosary, C. L., Yu, M., Ruhl, J., Tatalovich, Z., & Cho, H. (2014). SEER cancer statistics review, 1975–2010. *National Cancer Institute.*
3. Meza, R., & Chang, J. T. (2015). Multistage carcinogenesis and the incidence of thyroid cancer in the US by sex, race, stage and histology. *BMC public health*, 15(1), 1-9.
4. Wartofsky, L. (2010). Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? *Hormones*, 9(2), 103-8.
5. Imaizumi, M., Tominaga, T., Neriishi, K., Akahoshi, M., Nakashima, E., Ashizawa, K., ... & Eguchi, K. (2006). Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. *Jama*, *295*(9), 1011-1022.
6. Preston-Martin, S., Franceschi, S., Ron, E., & Negri, E. (2003). Thyroid cancer pooled analysis from 14 case-control studies: what have we learned?. *Cancer Causes & Control*, 787-789.
7. Kitahara, C. M., Platz, E. A., Freeman, L. E. B., Hsing, A. W., Linet, M. S., Park, Y., ... & Berrington de González, A. (2011). Obesity and thyroid cancer risk among US men and women: a pooled analysis of five prospective studies. *Cancer epidemiology, biomarkers & prevention*, *20*(3), 464-472.
8. Rinaldi, S., Lise, M., Clavel-Chapelon, F., Boutron-Ruault, M. C., Guillas, G., Overvad, K., ... & Franceschi, S. (2012). Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. *International journal of cancer*, *131*(6), E1004-E1014.
9. McLeod, D. S. (2014). Thyrotropin in the development and management of differentiated thyroid cancer. *Endocrinology and Metabolism Clinics*, *43*(2), 367-383.
10. Iribarren, C., Haselkorn, T., Tekawa, I. S., & Friedman, G. D. (2001). Cohort study of thyroid cancer in a San Francisco Bay area population. *International journal of cancer*, *93*(5), 745-750.
11. Franco, A. T., Malaguarnera, R., Refetoff, S., Liao, X. H., Lundsmith, E., Kimura, S., ... & Fagin, J. A. (2011). Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. *Proceedings of the National Academy of Sciences*, *108*(4), 1615-1620.
12. Jonklaas, J., Sarlis, N. J., Litofsky, D., Ain, K. B., Bigos, S. T., Brierley, J. D., ... & Sherman, S. I. (2006). Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid*, *16*(12), 1229-1242.
13. Moeller, L. C., & Führer, D. (2013). Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. *Endocr Relat Cancer*, *20*(2), R19-R29.
14. Ye, Z. Q., Gu, D. N., Hu, H. Y., Zhou, Y. L., Hu, X. Q., & Zhang, X. H. (2013). Hashimoto's thyroiditis, microcalcification and raised thyrotropin levels within normal range are associated with thyroid cancer. *World journal of surgical oncology*, *11*(1), 1-7.
15. Moon, S. S., Lee, Y. S., Lee, I. K., & Kim, J. G. (2012). Serum thyrotropin as a risk factor for thyroid malignancy in euthyroid subjects with thyroid micronodule. *Head & neck*, *34*(7), 949-952.
16. Gul, K., Ozdemir, D., Dirikoc, A., Oguz, A., Tuzun, D., Baser, H., ... & Cakir, B. (2010). Are endogenously lower serum thyroid hormones new predictors for thyroid malignancy in addition to higher serum thyrotropin?. *Endocrine*, *37*(2), 253-260.
17. Jonklaas, J., Nsouli-Maktabi, H., & Soldin, S. J. (2008). Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. *Thyroid*, *18*(9), 943-952.
18. Zafón, C., Obiols, G., & Mesa, J. (2015). Preoperative TSH level and risk of thyroid cancer in patients with nodular thyroid disease: nodule

size contribution. *Endocrinología Y Nutrición*, *62*(1), 24-28.
19. Zimny, M., Selkinski, I., Blasius, S., Rink, T., Schroth, H. J., & Grünwald, F. (2012). Risk of malignancy in follicular thyroid neoplasm. *Nuklearmedizin-NuclearMedicine*, *51*(04), 119-124.
20. Chiu, H. K., Sanda, S., Fechner, P. Y., & Pihoker, C. (2012). Correlation of TSH with the risk of paediatric thyroid carcinoma. *Clinical endocrinology*, *77*(2), 316-322.
21. Dorange, A., Triau, S., Mucci-Hennekinne, S., Bizon, A., Laboureau-Soares, S., Illouz, F., ... & Rohmer, V. (2011, December). An elevated level of TSH might be predictive of differentiated thyroid cancer. In *Annales d'endocrinologie* (Vol. 72, No. 6, pp. 513-521). Elsevier Masson.
22. Haymart, M. R., Repplinger, D. J., Leverson, G. E., Elson, D. F., Sippel, R. S., Jaume, J. C., & Chen, H. (2008). Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. *The Journal of Clinical Endocrinology & Metabolism*, *93*(3), 809-814.
23. Fiore, E., Rago, T., Provenzale, M. A., Scutari, M., Ugolini, C., Basolo, F., ... & Vitti, P. (2010). L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. *Endocrine-related cancer*, *17*(1), 231.
24. Zafon, C., Obiols, G., Baena, J. A., Castellví, J., Dalama, B., & Mesa, J. (2012). Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. *Journal of thyroid research*, *2012*.
25. Shi, L., Li, Y., Guan, H., Li, C., Shi, L., Shan, Z., & Teng, W. (2012). Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1870 Chinese patients with thyroid nodules. *Endocrine journal*, EJ12-0154.
26. Jin, J., Machekano, R., & McHenry, C. R. (2010). The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease. *The American journal of surgery*, 199(3), 294-8.
27. Kim, E. S., Lim, D. J., Baek, K. H., Lee, J. M., Kim, M. K., Kwon, H. S., ... & Son, H. Y. (2010). Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. *Thyroid*, *20*(8), 885-891.
28. Nixon, I. J., Ganly, I., Hann, L. E., Lin, O., Yu, C., Brandt, S., ... & Patel, S. G. (2010). Nomogram for predicting malignancy in thyroid nodules using clinical, biochemical, ultrasonographic, and cytologic features. *Surgery*, *148*(6), 1120-1128.
29. Boelaert, K., Horacek, J., Holder, R. L., Watkinson, J. C., Sheppard, M. C., & Franklyn, J. A. (2006). Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *The Journal of Clinical Endocrinology & Metabolism*, *91*(11), 4295-4301.
30. Kim, H. K., Yoon, J. H., Kim, S. J., Cho, J. S., Kweon, S. S., & Kang, H. C. (2013). Higher TSH level is a risk factor for differentiated thyroid cancer. *Clinical Endocrinology*, *78*(3), 472-477.
31. Gerschpacher, M., Göbl, C., Anderwald, C., Gessl, A., & Krebs, M. (2010). Thyrotropin serum concentrations in patients with papillary thyroid microcancers. *Thyroid*, *20*(4), 389-392.
32. Kim, K. W., Park, Y. J., Kim, E. H., Park, S. Y., Park, D. J., Ahn, S. H., ... & Cho, B. Y. (2011). Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. *Head & neck*, *33*(5), 691-695.
33. Petric, R., Perhavec, A., Gazic, B., & Besic, N. (2012). Preoperative serum thyroglobulin concentration is an independent predictive factor of malignancy in follicular neoplasms of the thyroid gland. *Journal of surgical oncology*, *105*(4), 351-356.
34. Polyzos, S. A., Kita, M., Efstathiadou, Z., Poulakos, P., Slavakis, A., Sofianou, D., ... & Avramidis, A. (2008). Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. *Journal of cancer research and clinical oncology*, *134*(9), 953-960.